Could a Two-Drug HIV pill be enough for transgender women?
NCT ID NCT06967753
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study is for transgender women with HIV who are already on a stable three-drug regimen. It tests switching to a simpler two-drug combination (dolutegravir plus lamivudine) to see if it keeps the virus under control. About 50 participants will take the two-drug pill for 48 weeks, and researchers will monitor viral levels and safety. The goal is to offer a more convenient treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General de Agudos Dr. Juan A. Fernández, Infectious Diseases Division
RECRUITINGBuenos Aires, Buenos Aires F.D., 1425, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.